Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Investment analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for Monopar Therapeutics in a report released on Monday, January 6th. Brookline Capital Management analyst K. Dolliver expects that the company will earn ($0.78) per share for the quarter. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics' Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.27) EPS and FY2025 earnings at ($4.07) EPS.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.46) by $0.09.
MNPR has been the topic of a number of other research reports. HC Wainwright boosted their price objective on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the company a "buy" rating in a research report on Monday, November 11th. Rodman & Renshaw assumed coverage on Monopar Therapeutics in a report on Friday, October 11th. They set a "buy" rating and a $50.00 price objective on the stock.
Check Out Our Latest Report on Monopar Therapeutics
Shares of MNPR stock opened at $24.46 on Thursday. The stock's 50 day simple moving average is $21.43 and its two-hundred day simple moving average is $10.45. Monopar Therapeutics has a 1 year low of $1.54 and a 1 year high of $38.50. The company has a market cap of $129.10 million, a PE ratio of -12.42 and a beta of 1.23.
In other Monopar Therapeutics news, CFO Karthik Radhakrishnan purchased 1,550 shares of the stock in a transaction on Monday, October 28th. The stock was acquired at an average price of $16.25 per share, with a total value of $25,187.50. Following the completion of the acquisition, the chief financial officer now owns 1,550 shares in the company, valued at $25,187.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 34.90% of the company's stock.
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.